The U.S Food and Drug Administration has approved Nucala, British drugmaker GSK's asthma drug, to treat some patients with a ...

GSK plc (NYSE:GSK) has strengthened its market outlook following major regulatory milestones. The U.S. FDA’s recent approval ...

Myanmar has faced substantial disruption, with impacts on respiratory health, in the aftermath of a devastating 7·7 magnitude ...

St. Louis can either use the disaster as an opportunity to commit to the safety of all its residents, or it can continue a ...

The U.S. Food and Drug Administration has approved Nucala (mepolizumab) as an add-on maintenance treatment for adult patients ...

GSK stock dips 0.6% after six-session gain streak. EU panel backs Blenrep for multiple myeloma, while FDA expands asthma ...

Mepolizumab has had a bumpy road to arriving at its indication in COPD. An FDA advisory committee in 2018 declined to ...

The U.S. Food and Drug Administration has approved British drugmaker GSK's asthma drug to treat some patients with a chronic ...

Many power plants benefiting from exemptions rank among the nation’s worst polluters. The Trump administration says cheaper ...

Rate this content's potential impact on patient outcomes Submit Rating Average rating / 5. Vote count: No votes so far! Be the first to ...

The FDA has approved Nucala (mepolizumab) as an add-on maintenance treatment for certain COPD patients whose disease isn't ...

The FDA has granted approval to GSK's Nucala as an add-on maintenance treatment for adult patients suffering from inadequately controlled COPD.